Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment (Q38889962)

7 September 2017

title

Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment (English)

1 reference

7 September 2017

main subject

prolymphocytic leukemia

1 reference

Aude Collignon

1 reference

7 September 2017

Anne Wanquet

1 reference

7 September 2017

Elsa Maitre

1 reference

7 September 2017

Edouard Cornet

1 reference

7 September 2017

Xavier Troussard

1 reference

7 September 2017

Thérèse Aurran-Schleinitz

1 reference

7 September 2017

publication date

1 April 2017

1 reference

7 September 2017

published in

Current Oncology Reports

1 reference

7 September 2017

1 reference

7 September 2017

1 reference

7 September 2017

1 reference

How I treat prolymphocytic leukemia

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Deciphering leukemic B-cell chronic lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Splenic B-cell lymphomas with more than 55% prolymphocytes in blood: evidence for prolymphocytoid transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Improvement of the Chronic Lymphocytic Leukemia Scoring System With the Monoclonal Antibody SN8(CD79b)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Cytogenetic abnormalities in three patients with B-cell prolymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Frequent deletions at 11q23 and 13q14 in B cell prolymphocytic leukemia (B-PLL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Aberrations of MYC are a common event in B-cell prolymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

De novo B-cell prolymphocytic leukemia with central nervous system involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Allogeneic hematopoietic cell transplant for prolymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Successful allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for B-cell prolymphocytic leukemia in partial remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

T-cell chronic lymphocytic leukemia with a helper/inducer membrane phenotype: a distinct clinicopathologic subtype with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Prolymphocytic leukaemia of B and T cell type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

The morphological spectrum of T-prolymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

T-cell prolymphocytic leukemia with autoimmune manifestations in Nijmegen breakage syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

T-cell chronic lymphocytic leukemia or small-cell variant of T-cell prolymphocytic leukemia: a historical perspective and search for consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Deregulated expression of TCL1 causes T cell leukemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Trisomy 8q due to i(8q) or der(8) t(8;8) is a frequent lesion in T-prolymphocytic leukaemia: four new cases and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Survival trends in T cell prolymphocytic leukemia: A SEER database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Primary refractory T-cell prolymphocytic leukaemia treated with daily administration of Alemtuzumab plus high-dose methylprednisolone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Reduced-Intensity Allogeneic Transplantation Provides High Event-Free and Overall Survival in Patients with Advanced Indolent B Cell Malignancies: CALGB 109901

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Phase I trial of nelarabine in indolent leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

High levels of chromosomal imbalances in typical and small-cell variants of T-cell prolymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0581-X

The first case of de novo B-cell prolymphocytic leukemia with central nervous system involvement: description of an unreported complication

21 January 2018

1 reference

12 December 2020

Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia

1 reference

12 December 2020

Possible specific chromosome change in prolymphocytic leukemia

1 reference

12 December 2020

From the R.E.A.L. Classification to the upcoming WHO scheme: a step toward universal categorization of lymphoma entities?

1 reference

12 December 2020

B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures

1 reference

12 December 2020

High frequency of somatic mutations in the VH genes expressed in prolymphocytic leukemia.

1 reference

12 December 2020

The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL

1 reference

12 December 2020

Immunoblastic sarcoma of T-cell versus B-cell origin: I. Clinical features

1 reference

12 December 2020

Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma

1 reference

12 December 2020

Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course

1 reference

12 December 2020

Allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning in primary refractory prolymphocytic leukemia: graft-versus-leukemia effect without graft-versus-host disease

1 reference

12 December 2020

Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Français d'Hématologie Cellulaire

1 reference

12 December 2020

Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia

1 reference

12 December 2020

Allogeneic peripheral stem-cell transplantation with reduced-intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: a long-term follow-up

1 reference

12 December 2020

Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC)

1 reference

12 December 2020

The nature of T-chronic lymphocytic leukaemia

1 reference

12 December 2020

p53 abnormalities in B-cell prolymphocytic leukemia.

1 reference

12 December 2020

Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study

1 reference

12 December 2020

The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group

1 reference

12 December 2020

Tac-positive, HTLV-negative, T helper phenotype chronic lymphocytic leukemia cells.

1 reference

12 December 2020

Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia

1 reference

12 December 2020

Management of prolymphocytic leukemia.

1 reference

12 December 2020

Bendamustine is effective in T-cell prolymphocytic leukaemia

1 reference

12 December 2020

Cutaneous infiltration in T-cell prolymphocytic leukaemia

1 reference

12 December 2020

True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases.

1 reference

12 December 2020

A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia

1 reference

12 December 2020

Prolymphocytic leukemia: clinical, histopathological, and cytochemical observations

1 reference

12 December 2020

Inactivation of the ATM gene in T-cell prolymphocytic leukemias.

1 reference

12 December 2020

Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia

1 reference

12 December 2020

The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype

1 reference

12 December 2020

Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia

1 reference

12 December 2020

Chromosome abnormalities in B-cell prolymphocytic leukemia: a study of nine cases

1 reference

12 December 2020

An Unusual Cause of Delirium and Debility: Refractory Hypercalcemia in a Man with B-Cell Prolymphocytic Leukemia

1 reference

12 December 2020

T-cell prolymphocytic leukemia: survival improves with alemtuzemab, but stem cell transplant eligibility 'counts' even more

1 reference

12 December 2020

The WHO classification of mature T-cell leukemias

1 reference

12 December 2020

Complete response to alemtuzumab in a patient with B prolymphocytic leukemia

1 reference

12 December 2020

Nucleolated variant of mantle cell lymphoma with leukemic manifestations mimicking prolymphocytic leukemia

1 reference

12 December 2020

T cell chronic lymphocytic leukemia with bullous manifestations

1 reference

12 December 2020

Further characterization of morphologically defined typical and atypical CLL: a clinical, immunophenotypic, cytogenetic and prognostic study on 390 cases

1 reference

12 December 2020

Cytogenetic studies on prolymphocytic leukemia. II. T cell prolymphocytic leukemia

1 reference

12 December 2020

Prolymphocytic leukaemia

1 reference

12 December 2020

Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route

1 reference

12 December 2020

B cell prolymphocytic leukaemia (B-PLL) with complex karyotype and concurrent abnormalities of the p53 and c-MYC gene

1 reference

12 December 2020

10.1007/S11912-017-0581-X

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

1084033427

0 references

1 reference